{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:07:24Z","timestamp":1790395644181,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,4]],"date-time":"2015-08-04T00:00:00Z","timestamp":1438646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"NIHR Doctoral Research Fellowship","award":["2009-02-112"],"award-info":[{"award-number":["2009-02-112"]}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research (NIHR)","doi-asserted-by":"crossref","award":["PB-PG-1207-15025"],"award-info":[{"award-number":["PB-PG-1207-15025"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","cysticfibrosisjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.jcf.2015.07.012","type":"journal-article","created":{"date-parts":[[2015,8,15]],"date-time":"2015-08-15T19:02:17Z","timestamp":1439665337000},"page":"510-517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison"],"prefix":"10.1016","volume":"15","author":[{"given":"A.P.","family":"Prayle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.","family":"Touw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.C.P.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Knox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.R.","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2015.07.012_bb0005","series-title":"UK Cystic Fibrosis Registry","author":"Trust","year":"2014"},{"issue":"6","key":"10.1016\/j.jcf.2015.07.012_bb0010","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/thx.2006.067595","article-title":"Survey of acute renal failure in patients with cystic fibrosis in the UK","volume":"62","author":"Bertenshaw","year":"2007","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.jcf.2015.07.012_bb0015","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1136\/thx.2007.088757","article-title":"Case\u2013control study of acute renal failure in patients with cystic fibrosis in the UK","volume":"63","author":"Smyth","year":"2008","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.jcf.2015.07.012_bb0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ppul.20138","article-title":"Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use","volume":"39","author":"Al-Aloul","year":"2005","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.jcf.2015.07.012_bb0025","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/00007691-199302000-00010","article-title":"Validation of tobramycin monitoring in adolescent and adult patients with cystic fibrosis","volume":"15","author":"Touw","year":"1993","journal-title":"Ther Drug Monit"},{"issue":"9459","key":"10.1016\/j.jcf.2015.07.012_bb0030","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(05)17906-9","article-title":"Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis\u2014the TOPIC study: a randomised controlled trial","volume":"365","author":"Smyth","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jcf.2015.07.012_bb0035","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jcf.2013.11.007","article-title":"Prescribing practices for intravenous aminoglycosides in UK Cystic Fibrosis clinics: A questionnaire survey","volume":"13","author":"Smyth","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2015.07.012_bb0040","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0378-4274(88)90159-2","article-title":"Circadian variations in the renal toxicity of gentamicin in rats","volume":"40","author":"Pariat","year":"1988","journal-title":"Toxicol Lett"},{"issue":"3","key":"10.1016\/j.jcf.2015.07.012_bb0045","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0024-3205(94)00877-9","article-title":"Nephrotoxicity of low-doses of tobramycin in rats\u2014Effect of the time of administration","volume":"55","author":"Lin","year":"1994","journal-title":"Life Sci"},{"issue":"3","key":"10.1016\/j.jcf.2015.07.012_bb0050","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00007691-200006000-00012","article-title":"Diurnal changes in the pharmacokinetic behavior of amikacin","volume":"22","author":"Bleyzac","year":"2000","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.jcf.2015.07.012_bb0055","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0009-9236(97)90156-9","article-title":"Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients","volume":"62","author":"Prins","year":"1997","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jcf.2015.07.012_bb0060","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF00280062","article-title":"Chronokinetic study of netilmicin in man","volume":"39","author":"Lucht","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.jcf.2015.07.012_bb0065","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/j.1552-4604.1990.tb01876.x","article-title":"Circadian variation in serum amikacin levels","volume":"30","author":"Elting","year":"1990","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.jcf.2015.07.012_bb0070","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1128\/AAC.38.3.620","article-title":"Fever and associated changes in glomerular filtration rate erase anticipated diurnal variations in aminoglycoside pharmacokinetics","volume":"38","author":"Fauvelle","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.jcf.2015.07.012_bb0075","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jcf.2006.12.007","article-title":"Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis","volume":"6","author":"Touw","year":"2007","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2015.07.012_bb0080","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/074873002129002474","article-title":"Comparisons of the variability of three markers of the human circadian pacemaker","volume":"17","author":"Klerman","year":"2002","journal-title":"J Biol Rhythms"},{"key":"10.1016\/j.jcf.2015.07.012_bb0085","series-title":"Antibiotic treatment for cystic fibrosis","author":"UK CF Trust Antibiotic Working Group","year":"2009"},{"issue":"2","key":"10.1016\/j.jcf.2015.07.012_bb0090","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2869.2005.00451.x","article-title":"Prediction of melatonin efficacy by pretreatment dim light melatonin onset in children with idiopathic chronic sleep onset insomnia","volume":"14","author":"der Heijden KB","year":"2005","journal-title":"J Sleep Res"},{"issue":"11","key":"10.1016\/j.jcf.2015.07.012_bb0095","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1515\/JPEM.2009.22.11.1009","article-title":"Daily profiles of salivary and urinary melatonin and steroids in healthy prepubertal boys","volume":"22","author":"Touitou","year":"2009","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.jcf.2015.07.012_bb0100","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.pediatrneurol.2011.11.018","article-title":"Diurnal melatonin patterns in children: ready to apply in clinical practice?","volume":"46","author":"Praninskiene","year":"2012","journal-title":"Pediatr Neurol"},{"issue":"2","key":"10.1016\/j.jcf.2015.07.012_bb0105","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1542\/peds.58.2.259","article-title":"A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine","volume":"58","author":"Schwartz","year":"1976","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.jcf.2015.07.012_bb0110","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2015.07.012_bb0115","series-title":"R: A language and environment for statistical computing. 2.15.0 ed","author":"R Development Core Team","year":"2012"},{"issue":"4","key":"10.1016\/j.jcf.2015.07.012_bb0120","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2165\/00003088-198713040-00002","article-title":"Antibiotic pharmacokinetics in cystic-fibrosis\u2014Differences and clinical-significance","volume":"13","author":"de Groot","year":"1987","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.jcf.2015.07.012_bb0125","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1042\/cs0770105","article-title":"Circadian-rhythm of glomerular-filtration rate in normal individuals","volume":"77","author":"Koopman","year":"1989","journal-title":"Clin Sci"},{"issue":"8","key":"10.1016\/j.jcf.2015.07.012_bb0130","doi-asserted-by":"crossref","first-page":"e43809","DOI":"10.1371\/journal.pone.0043809","article-title":"Mechanism-based urinary biomarkers to identify the potential for aminoglycoside-induced nephrotoxicity in premature neonates: a proof-of-concept study","volume":"7","author":"McWilliam","year":"2012","journal-title":"PLoS One"},{"issue":"13, Supplement 2(0)","key":"10.1016\/j.jcf.2015.07.012_bb0135","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/S1569-1993(14)60202-2","article-title":"Association of urinary kidney injury molecule-1 with aminoglycoside exposure in children with cystic fibrosis","volume":"6","author":"McWilliam","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2015.07.012_bb0140","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1074\/jbc.273.7.4135","article-title":"Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury","volume":"273","author":"Ichimura","year":"1998","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.jcf.2015.07.012_bb0145","doi-asserted-by":"crossref","first-page":"F552","DOI":"10.1152\/ajprenal.00285.2002","article-title":"Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury","volume":"286","author":"Ichimura","year":"2004","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"10.1016\/j.jcf.2015.07.012_bb0150","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/ndt\/gfs380","article-title":"Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature","volume":"28","author":"Vanmassenhove","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.jcf.2015.07.012_bb0155","doi-asserted-by":"crossref","first-page":"e84131","DOI":"10.1371\/journal.pone.0084131","article-title":"Diagnostic value of urinary kidney injury molecule 1 for acute kidney injury: a meta-analysis","volume":"9","author":"Shao","year":"2014","journal-title":"PLoS One"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199315001745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199315001745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T13:54:22Z","timestamp":1653054862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199315001745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S1569199315001745"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2015.07.012","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2015.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}